The effectiveness of fluoxetine on the treatment of adaptive spasm caused by anxiety

Not Applicable

Conditions: Accommodative spasm.
Disorders of accommodation
H52.5

Registration Number: IRCT20240617062160N1

Lead Sponsor: Shahid Beheshti University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Pending

Sex: All

Target Recruitment: 68

Inclusion Criteria

Having eye spasms with symptoms
Bilateral accommodative spasm (there should be conditions in both eyes and it should not be unilateral)
No history of underlying diseases
Absence of strabismus

Exclusion Criteria

Uncorrected hyperopia
Having systemic diseases
Having pathological anxiety
Having eye diseases such as keratoconus, cataract, uveitis, retinal retinopathy, and all diseases that affect the quality of vision and visual system of the patient.

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Dry refractive error. Timepoint: At the beginning of the study (before the start of the intervention), 5 weeks after the start of fluoxetine, and 3 months after the start of vision therapy. Method of measurement: Autorefractometer device.;Cyclo refractive error. Timepoint: At the beginning of the study (before the start of the intervention), 5 weeks after the start of fluoxetine, and 3 months after the start of vision therapy. Method of measurement: Autorefractometer device.;Best corrected visual acuity. Timepoint: At the beginning of the study (before the start of the intervention), 5 weeks after the start of fluoxetine, and 3 months after the start of vision therapy. Method of measurement: Glasses or contact lenses.

Secondary Outcome Measures

Name	Time	Method
Amplitude of accommodation. Timepoint: En At the beginning of the study (before the start of the intervention), 5 weeks after the start of fluoxetine, and 3 months after the start of vision therapy. Method of measurement: Dynamic retinoscopy.;Facility of accommodation. Timepoint: En At the beginning of the study (before the start of the intervention), 5 weeks after the start of fluoxetine, and 3 months after the start of vision therapy. Method of measurement: Dynamic retinoscopy.